Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 111975
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.111975
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.111975
Long-term survival after multimodality treatment of metastatic mixed adenoneuroendocrine carcinoma of colon: A case report
Jun Pan, Lu Lu, Yi-Tian Chen, Xiao-Yuan Chu, Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu Province, China
Rong-Sheng Zhang, Department of Hepatobiliary Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 211112, Jiangsu Province, China
Ying Chen, Department of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 430014, China
Xiao-Hui Cao, Zhi-Hui Yang, Department of Pathology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu Province, China
Co-first authors: Jun Pan and Rong-Sheng Zhang.
Co-corresponding authors: Yi-Tian Chen and Xiao-Yuan Chu.
Author contributions: Pan J drafted the manuscript; Zhang RS was the patient’s surgeon and acquired the data; Cao XH and Yang ZH analyzed and interpreted Pathology; Chen Y and Lu L analyzed and interpreted the imaging findings; Pan J, Chen YT and Chu XY contributed to the study conception and design. Pan J and Zhang RS contributed equally to this work as co-first authors. The corresponding author of this study is Chu XY, and the co-corresponding author is Chen YT. The first corresponding author, Chu XY, is responsible for the article design, data analysis, and guiding the writing of the paper. The co-corresponding author, Chen YT, plays a key role in the article design and cross-team coordination. Therefore, this study has two co-corresponding authors.
Informed consent statement: Written informed consent was obtained from participant.
Conflict-of-interest statement: We declare that we have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yuan Chu, MD, Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210008, Jiangsu Province, China. chuxiaoyuan0@163.com
Received: July 16, 2025
Revised: August 4, 2025
Accepted: August 15, 2025
Published online: October 27, 2025
Processing time: 100 Days and 22.9 Hours
Revised: August 4, 2025
Accepted: August 15, 2025
Published online: October 27, 2025
Processing time: 100 Days and 22.9 Hours
Core Tip
Core Tip: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare type of malignant tumor, but there is no standard treatment protocol. This article reviews a case of a patient diagnosed with liver metastasis from ascending colon MANEC. The patient experienced multiple recurrent liver metastases. Through a multidisciplinary treatment approach including chemotherapy, surgical resection, and radiofrequency ablation, the patient achieved complete response and a long-term survival of ten years. The comprehensive treatment approach has shown encouraging results for MANEC and is worthy of further study.